PLAA suppresses ovarian cancer metastasis via METTL3-mediated m6A modification of TRPC3 mRNA

Zhangjin Shen1, Lingkai Gu1, Yuwan Liu1, Lingfang Wang1, Jiawei Zhu2, Sangsang Tang1, Xinyi Wei1, Jiaying Wang3, Songfa Zhang2, Xinyu Wang2,4,5, Xiaodong Cheng2,4,6, Xing Xie2 and Weiguo Lu2,4,6

© The Author(s) 2022

Wide metastasis contributes to a high death rate in ovarian cancer, and understanding of the molecular mechanism helps to find effective targets for metastatic ovarian cancer therapy. It has been found that phospholipase A2-activating protein (PLAA) is inactivated in some cancers, but its role in cancer metastasis remains unknown. Here, we found that PLAA was significantly downregulated in ovarian cancer highly metastatic cell lines and patients, and the low expression of PLAA was associated with poorer prognosis and high-risk clinicopathological features of patients. PLAA inhibited the migration and invasion of ovarian cancer cells and metastasis of transplanted tumor in the orthotopic xenograft mouse model. Meanwhile, PLAA inhibited metastasis of ovarian cancer by inhibiting transient receptor potential channel canonical 3 (TRPC3)-mediated the intracellular Ca2+ level. Mechanistically, PLAA inhibited methyltransferase-like 3 (METTL3) expression through the ubiquitin-mediated degradation, and METTL3 stabilized TRPC3 mRNA expression via N6-methyladenosine (m6A) modification. Our study verified the function and mechanism of the PLAA-METTL3-TRPC3 axis involved in ovarian cancer metastasis, with a view to providing a potential therapeutic approach for ovarian cancer.

Oncogene (2022) 41:4145–4158; https://doi.org/10.1038/s41388-022-02411-w

INTRODUCTION

Epithelial ovarian cancer is the most lethal gynecological malignancy worldwide [1, 2]. One of the most important biological characteristics of ovarian cancer is its insidious and rapid spread from the primary tumor into the peritoneal cavity, involving almost all abdominal organs, and distant organs, which contributes to the high death rate of disease [3, 4]. Accordingly, it is urgent to understand the biological process of ovarian cancer metastasis, so as to find effective therapeutic target for metastatic ovarian cancer.

Multiple signal pathways are involved in cancer metastasis. We thus profiled a pair of epithelial ovarian cancer cell lines with different metastatic potentials [5] by using proteomics, and discovered that phospholipase A2-activating protein (PLAA) was downregulated in highly metastatic ovarian cancer cells. PLAA is encoded by gene PLAA that is located on chromosome 9p21 [6]. It has been verified that PLAA has a highly homologous sequence with yeast Ufd3/Doa1 [7], but little is known about its biological function so far, such as the endo-lysosomal damage response [8]. PLAA has been reported to be associated with leukoencephalopathy [9]. Previous studies showed that PLAA was inactivated in some cancers, including ovarian, lung, and breast cancer [10], and the application of PLAA polypeptide led to tumor regression in animal models of lung and breast cancer [11]. However, the role of PLAA in cancer metastasis is poorly known to date.

In the present study, we found that PLAA expression was significantly downregulated in ovarian cancer tissues, and patients with lower PLAA expression presented poorer prognosis. Functionally, PLAA suppressed migration and invasion of ovarian cancer cells and metastasis in the orthotopic xenograft mouse model. Mechanistically, PLAA inhibited METTL3 expression through the ubiquitin-mediated degradation and destabilized TRPC3 expression via METTL3-mediated m6A modification, which consequently suppressed intracellular calcium concentration and ovarian cancer metastasis. To the best of our knowledge, our findings is the first to demonstrate a suppressive role and the underlying mechanism of PLAA in ovarian cancer, which may provide a potential therapeutic approach for ovarian cancer metastasis.

RESULTS

PLAA is downregulated in ovarian cancer and positively correlated with prognosis

A2780-M cell line with highly metastatic ability [5] and the parental cell line were selected for the protein expression profiles by liquid chromatography (LC)-mass spectrometry (MS)/MS label-free quantitative proteomics, and PLAA was identified as one of the most significantly downregulated proteins in highly metastatic cells (Fig. 1A). A typical MS spectrum of PLAA is shown in Fig. 1B.

1Women’s Reproductive Health Laboratory of Zhejiang Province, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006 Zhejiang, China. 2Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006 Zhejiang, China. 3Department of Obstetrics and Gynecology, the Seventh Medical Centre, Chinese PLA General Hospital, Beijing 100853, China. 4Cancer Center, Zhejiang University, Hangzhou 310058 Zhejiang, China. 5Department of Obstetrics and Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003 Zhejiang, China. 6Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006 Zhejiang, China. 7email: lbwg@zju.edu.cn

Received: 4 April 2022 Revised: 1 July 2022 Accepted: 7 July 2022
Published online: 22 July 2022

© The Author(s) 2022

Oncogene (2022) 41:4145–4158; https://doi.org/10.1038/s41388-022-02411-w

ARTICLE OPEN

Wide metastasis contributes to a high death rate in ovarian cancer, and understanding of the molecular mechanism helps to find effective targets for metastatic ovarian cancer therapy. It has been found that phospholipase A2-activating protein (PLAA) is inactivated in some cancers, but its role in cancer metastasis remains unknown. Here, we found that PLAA was significantly downregulated in ovarian cancer highly metastatic cell lines and patients, and the low expression of PLAA was associated with poorer prognosis and high-risk clinicopathological features of patients. PLAA inhibited the migration and invasion of ovarian cancer cells and metastasis of transplanted tumor in the orthotopic xenograft mouse model. Meanwhile, PLAA inhibited metastasis of ovarian cancer by inhibiting transient receptor potential channel canonical 3 (TRPC3)-mediated the intracellular Ca2+ level. Mechanistically, PLAA inhibited methyltransferase-like 3 (METTL3) expression through the ubiquitin-mediated degradation, and METTL3 stabilized TRPC3 mRNA expression via N6-methyladenosine (m6A) modification. Our study verified the function and mechanism of the PLAA-METTL3-TRPC3 axis involved in ovarian cancer metastasis, with a view to providing a potential therapeutic approach for ovarian cancer.

Oncogene (2022) 41:4145–4158; https://doi.org/10.1038/s41388-022-02411-w

© The Author(s) 2022

INTRODUCTION

Epithelial ovarian cancer is the most lethal gynecological malignancy worldwide [1, 2]. One of the most important biological characteristics of ovarian cancer is its insidious and rapid spread from the primary tumor into the peritoneal cavity, involving almost all abdominal organs, and distant organs, which contributes to the high death rate of disease [3, 4]. Accordingly, it is urgent to understand the biological process of ovarian cancer metastasis, so as to find effective therapeutic target for metastatic ovarian cancer.

Multiple signal pathways are involved in cancer metastasis. We thus profiled a pair of epithelial ovarian cancer cell lines with different metastatic potentials [5] by using proteomics, and discovered that phospholipase A2-activating protein (PLAA) was downregulated in highly metastatic ovarian cancer cells. PLAA is encoded by gene PLAA that is located on chromosome 9p21 [6]. It has been verified that PLAA has a highly homologous sequence with yeast Ufd3/Doa1 [7], but little is known about its biological function so far, such as the endo-lysosomal damage response [8]. PLAA has been reported to be associated with leukoencephalopathy [9]. Previous studies showed that PLAA was inactivated in some cancers, including ovarian, lung, and breast cancer [10], and the application of PLAA polypeptide led to tumor regression in animal models of lung and breast cancer [11]. However, the role of PLAA in cancer metastasis is poorly known to date.

In the present study, we found that PLAA expression was significantly downregulated in ovarian cancer tissues, and patients with lower PLAA expression presented poorer prognosis. Functionally, PLAA suppressed migration and invasion of ovarian cancer cells and metastasis in the orthotopic xenograft mouse model. Mechanistically, PLAA inhibited METTL3 expression through the ubiquitin-mediated degradation and destabilized TRPC3 expression via METTL3-mediated m6A modification, which consequently suppressed intracellular calcium concentration and ovarian cancer metastasis. To the best of our knowledge, our findings is the first to demonstrate a suppressive role and the underlying mechanism of PLAA in ovarian cancer, which may provide a potential therapeutic approach for ovarian cancer metastasis.

RESULTS

PLAA is downregulated in ovarian cancer and positively correlated with prognosis

A2780-M cell line with highly metastatic ability [5] and the parental cell line were selected for the protein expression profiles by liquid chromatography (LC)-mass spectrometry (MS)/MS label-free quantitative proteomics, and PLAA was identified as one of the most significantly downregulated proteins in highly metastatic cells (Fig. 1A). A typical MS spectrum of PLAA is shown in Fig. 1B.
**Fig. 1** PLAA is downregulated in ovarian cancer and positively correlated with prognosis. A Differentially expressed proteins were compared between A2780-M and A2780 by using LC-MS/MS label-free quantitative proteomics. B A typical MS spectrum of PLAA. Immunoblot (C) and RT-qPCR analysis (D) of PLAA in IOSE-80 and two pairs of ovarian cancer cells with different metastatic ability. E RT-qPCR analysis of PLAA expression in 56 tissue samples of ovarian cancer and 12 tissue samples of ovarian benign tumor. F Immunoblot analysis of PLAA expression in ovarian cancer tissues and ovarian benign tumor tissues. G Immunoblot analysis of PLAA expression in ovarian cancer tissues and matched metastatic ovarian cancer tissues. P: primary ovarian cancer tissues. M: metastatic ovarian cancer tissues. H Representative IHC staining images of PLAA in ovarian cancer tissues (×200 and ×400 magnifications). Kaplan–Meier analysis of progression-free survival of 79 ovarian cancer patients in our hospital (I) and patients from TCGA data (J) with different PLAA expression. Data are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
The endogenous expression of PLAA in ovarian cancer cell lines with different metastatic abilities, including A2780-M, A2780, HO8910PM, HO8910, and the normal ovarian epithelial cell line IOSE-80 were validated by western blot and RT-qPCR. The results showed that PLAA were lower in highly metastatic cell lines than those in parental cell lines, and were lower in ovarian cancer cells than those in normal ovarian cells (Fig. 1C, D). We additionally collected 56 fresh tissue samples of ovarian cancer and 12 fresh tissue samples of ovarian benign tumor for PLAA mRNA detection, and found PLAA mRNA was significantly lower in cancer tissues (Fig. 1E), especially reduced in patients with advanced stage than the early stage (Fig. S1A). Moreover, the same results were found in ovarian cancer from gene expression omnibus ( GEO) (Fig. S1B) and TCGA datasets (Fig. S1C). In addition, PLAA protein expression were detected to be significantly lower in ovarian cancer tissues that in that in benign tumor tissues (Fig. 1F; Fig. S1D). Interestingly, PLAA protein and mRNA expression was further decreased in metastatic ovarian cancer as compared with the primary ovarian cancer they were derived from (Fig. 1G; Fig. S1E).

To understand the clinical significance of PLAA, we retrospectively collected the clinicopathological data of 79 ovarian cancer patients and their formalin-fixed and paraffin-embedded tissue samples for immunohistochemistry of PLAA protein (Fig. 1H), and found the significant association of PLAA expression with FIGO stage, lymph node metastasis, and CA125 level in patients, as shown in Table 1 Kaplan–Meier survival analysis also revealed shorter progression-free survival (PFS) in patients with low PLAA expression than that in those with high PLAA expression (Fig. 1I). We additionally analyzed the data in TCGA database, and found the same results (Fig. 1J). Our data together suggest that patients with lower PLAA expression present shorter survival and PLAA may be a potential biomarker for predicting ovarian cancer prognosis.

PLAA inhibits ovarian cancer migration and invasion in vitro and in vivo
To affirm the biological function of PLAA in ovarian cancer, PLAA knockdown or PLAA-overexpressing cell lines were established (Fig. 2A–D; Fig. S2A–D). We found that PLAA overexpression dramatically inhibited cell migration and invasion (Fig. 2E, F; Fig. S2E, F), while PLAA downregulation promoted cell migration and invasion (Fig. 2G, H; Fig. S2G, H). However, PLAA had no effect on cell proliferation (Fig. S2I, J).

We next investigated the effect of PLAA on ovarian cancer metastasis in vivo utilizing the orthotopic xenograft model. PLAA overexpressing or empty plasmid labeled with luciferase was stably transfected into A2780-M cells (named A2780-M-PLAA-luc cells or A2780-M-control-luc cells). The left ovari of each SCID mouse was pulled out from the median abdominal incision and A2780-M-PLAA-luc or A2780-M-control-luc cells were orthotopically injected into the ovary sub epithelium (each group = 5) (Fig. 2L). In vivo imaging system (IVIS) was performed every week to monitor tumor progression, and mice were euthanized after 6 weeks. The primary and metastatic tumors were separately assessed via taking off the primary tumors (Fig. 2J). IVIS scan showed that PLAA overexpression significantly inhibited metastasis in the xenograft model compared with controls, without changing their primary tumors (Fig. 2K). Hematoxylin and eosin (H&E) staining displayed the typical morphology of primary tumor, omental, and intestinal metastasis of ovarian cancer (Fig. 2L). Immunohistochemistry staining assay showed the overexpression efficiency of PLAA in orthotopic xenograft model (Fig. 2M). Our results together demonstrate that PLAA acts as a tumor metastatic suppressor in ovarian cancer.

TRPC3 is negatively correlated with PLAA expression
To understand the underlying mechanism by which PLAA inhibits ovarian cancer metastasis, transcriptome sequencing was performed in A2780 cells with PLAA knockdown and without, respectively. Hierarchical clustering indicated 165 upregulated genes and 109 downregulated genes (log2 fold change > 1, p < 0.05) in cells with PLAA knockdown (Fig. 3A). We selected ten top upregulated and ten top downregulated genes to validate their expression in A2780 and HO8910 cells with PLAA knockdown or in A2780-M and HO8910PM cells with PLAA overexpression, and found that in those differentially expressed genes, TRPC3 was the only one that presented consistently upregulated expression in both cells and by both PLAA siRNAs (Figs. 3B; S3A). On the contrary, TRPC3 was downregulated in A2780-M and HO8910PM cells with PLAA overexpression (Figs. 3C; S3B), as well as in highly metastatic cells comparing to their parental cells (Figs. 3F; S3E). We further found a significant negative correlation of the expression between PLAA and TRPC3 mRNA in 56 cancer samples (Fig. 3G), and IHC staining assay also showed the negative correlation between PLAA and TRPC3 (Fig. 3H). Therefore, these observations validate that TRPC3 probably is the potential target of PLAA in ovarian cancer.

TRPC3 behaves as an onco gene and acts as a downstream target of PLAA
To further characterize the role of TRPC3 in ovarian cancer, we first detected the expression of TRPC3 in our clinical ovarian cancer samples. We validated that TRPC3 mRNA were dramatically upregulated in ovarian cancer tissues compared with benign ovarian tumor tissues (Fig. 4A), and were higher in late stages of ovarian cancer tissues compared with the early stages (Fig. 4B). Furthermore, a Kaplan–Meier survival analysis of TCGA database showed that higher TRPC3 expression is correlated with shorter progression-free survival (PFS) (Fig. 4C). Thus, we established TRPC3 knockdown or TRPC3 overexpressing cell models according to the basic TRPC3 level, and found that PLAA expression remained unaltered whether TRPC3 was knocked down or overexpressed (Figs. 4D, E; S4A–D), but transwell assay revealed that TRPC3 knockdown or treatment with Pyr3, an inhibitor of TRPC3, inhibited migration and invasion in A2780-M and HO8910PM cells (Figs. 4F, G; S4E, F), whereas TRPC3 overexpression presented an opposite effect (Fig. S4G).

Moreover, we observed that migration and invasion ability decreased by PLAA overexpression were retrieved by TRPC3 overexpression (Figs. 4H, S4H). Conversely, migration and invasion ability accelerated by PLAA knockdown were abrogated by TRPC3 siRNA or treatment with Pyr3 (Figs. 4I, S4I). Utilizing the orthotopic ovarian cancer mouse model again, we injected A2780-shNC-luc (n = 5) or A2780-shPLAA-luc cells into ovaries of mice (n = 10), and randomly divided A2780-shPLAA-luc group into two sub-groups (each sub-group = 5) at day 7 after implantation (Fig. S4J). Pyr3 or DMSO was intravenously injected twice a week from week 1 for 8 times, and then the mice were euthanized after 6 weeks. We found that the mice injected with A2780-shPLAA-luc, compared with the control group, showed wider metastasis, which was significantly abolished by Pyr3 treatment, but no significant changes were detected in primary tumors (Fig. 4J). Our results together suggest that PLAA inhibits ovarian cancer metastasis in a TRPC3 dependent manner.

PLAA inhibits ovarian cancer metastasis by attenuating TRPC3-mediated intracellular calcium level
TRPC3 is a high calcium permeability cationic channel that governs the calcium-related signaling [12]. Intracellular calcium, a versatile second messenger, participates in multiple biological behaviors, such as proliferation and metastasis in cancer cells [13, 14]. In the presence of external solution containing 1.8 mM free calcium, we observed that the intracellular Ca2+ level was decreased when TRPC3 was knocked down or treated with Pyr3.
Fig. 2  PLAA inhibits ovarian cancer migration and invasion in vitro and in vivo. A2780-M were transected with PLAA-overexpressing plasmid or empty plasmid (A, B). A2780 cells were transfected with two PLAA siRNAs or negative control (C, D). PLAA expression was determined by RT-qPCR (A, C) or immunoblot analysis (B, D). A2780-M cells were transfected with PLAA-overexpressing plasmid or empty plasmid. Cellular migration and invasion were detected by wound healing (E) and transwell assay (F). Scale bar, 100 μm. A2780 cells were transfected with two PLAA siRNAs or negative control. Cellular migration and invasion were detected by wound healing (G) and transwell assay (H). Scale bar, 100 μm. I Schematic protocol for establishment of orthotopic ovarian cancer mouse model. J Representative images of orthotopic mouse model at the time of execution. Left, intact IVIS image; middle, image of dissected primary tumor; right, image of metastatic tumor. K Ovarian cancer cells were orthotopically transplanted into SCID mice. Representative bioluminescence images of dissected primary and metastatic ovarian cancer at the time of execution. The photon count indicated the tumor burden. L Histological features of primary, omental and intestinal metastatic lesions in the mouse model (×200 and ×400 magnifications). M Representative IHC staining images of PLAA in orthotopic xenograft model (×200 and ×400 magnifications). Data are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Oncogene (2022) 41:4145 – 4158

Z. Shen et al.
Fig. 5A, B; SSA, B). On the contrary, intracellular Ca\(^{2+}\) level was increased when TRPC3 was overexpression and the increased Ca\(^{2+}\) level was retrieved by the treatment of BAPTA-AM, a well-recognized intracellular calcium chelator (Figs. 5C; 5C). We further observed the effect of Ca\(^{2+}\) influx on TRPC3 promoting ovarian cancer metastasis. As expected, we found that migration and invasion accelerated by TRPC3 overexpression were abrogated in A2780 and HO8910 cells treated by BAPTA-AM (Figs. 5D; 5D). Further, we employed the orthotopic mouse model. Mice were injected with A2780-M-luc (n = 15) cells and were randomly divided into three group (each group = 5) at day 7 after implantation (Fig. 5E), Pyr3, BAPTA-AM or DMSO was intravenously injected twice a week from week 1 for 8 times, and mice were euthanized after 6 weeks. Hematoxylin and eosin staining for the major organs showed that Pyr3 and BAPTA-AM had no significant adverse effects under our experimental condition (Fig. 5F). IVIS scan showed that metastasis was significantly inhibited in the xenograft model with Pyr3 or BAPTA-AM treatment compared with controls, but no significant changes were detected in primary tumors (Fig. 5E).

In addition, in the presence of external solution containing 1.8 mM free calcium, we found that TRPC3 downregulation or BAPTA-AM treatment dramatically decreased the level of intracellular Ca\(^{2+}\) elevated by PLAA downregulation (Figs. 5F; 5G). As expected, the migration and invasion accelerated by PLAA downregulation were also rescued by BAPTA-AM (Figs. 5G; 5H). Moreover, the elevation of TRPC3 mRNA and protein level induced by PLAA knockdown was also retrieved by attenuation of METTL3 (Figs. 6, K; S6C). Our results together indicate that PLAA regulates the expression of TRPC3 mRNA via m\(^A\)A modification.

### PLAA promotes METTL3 degradation via the ubiquitin-mediated pathway in ovarian cancer

Since PLAA regulates the expression of TRPC3 mRNA by m\(^A\)A modification, we detected m\(^A\)A modification related proteins, including writers (m\(^A\)A methyltransferases, including METTL3, METTL14 and WTAP) and erasers (m\(^A\)A demethylases, including FTO and ALKBH5). As expected, we found that METTL3, but not others, was remarkably elevated in cells with PLAA knockdown (Fig. 7A), suggesting that TRPC3 mRNA was regulated by METTL3. In addition, RNA immunoprecipitation assay showed that METTL3-specific antibody dramatically enriched TRPC3 mRNA, compared to the IgG control, while PLAA knockdown significantly intensified the enrichment of TRPC3 mRNA in A2780 and HO8910 cells (Fig. 7B). Considering that PLAA knockdown had no effect on the mRNA level of METTL3 (Fig. 7C), we suggested changes at protein level may be the main reason for METTL3 upregulation in the PLAA downregulated group. Thus, we treated A2780 and HO8910 cells with cycloheximide (CHX) to inhibit protein biosynthesis, and found a significantly extended half-life of METTL3 protein in cells with PLAA knockdown (Fig. 7D). We further observed the restored METTL3 protein expression in A2780-M and HO8910PM cells with PLAA overexpression after the treatment of proteasome inhibitor MG132, but not lysosomal autophagy inhibitor chloroquine (CQ) (Fig. 7E). These results suggested that METTL3 was degraded via the ubiquitin-mediated degradation pathway. Thus, we performed the ubiquitination experiment, and found that PLAA down-regulation reduced ubiquitination of METTL3 in A2780 and HO8910 cells as expected (Fig. 7F). These results suggest that PLAA inhibits METTL3 protein expression via the ubiquitin-mediated degradation pathway.

### DISCUSSION

Previous studies revealed that PLAA inactivity was associated with ovarian and other cancers [10, 11]. In this study, we observed that PLAA expression was significantly downregulated in two highly metastatic ovarian cancer cells than that in lower metastatic cells, and in ovarian cancer tissues compared to ovarian benign tumor tissues. In addition, PLAA expression was decreased in metastatic ovarian cancer tissues as compared with the primary ovarian cancer tissues that they were derived from. Although the reason for the decline of PLAA expression is not clear to date, our in vitro

---

**Table 1. Clinical characteristics of 79 ovarian cancer patients depending on PLAA protein level.**

| variable                  | N   | PLAA expression | P value |
|---------------------------|-----|-----------------|---------|
|                           |     | Low | High |        |
| Age (years)               |     |     |      |        |
| ≤50                       | 30  | 16  | 14   | 0.581  |
| >50                       | 49  | 23  | 26   |        |
| FIGO stage                |     |     |      |        |
| I/II                      | 32  | 8   | 24   | 0.001**|
| III/IV                    | 47  | 31  | 16   |        |
| Lymph node metastasis     |     |     |      |        |
| Negative                  | 66  | 27  | 39   | 0.001**|
| Positive                  | 13  | 12  | 1    |        |
| Ascitic fluid volume (ml) |     |     |      |        |
| <500                      | 51  | 22  | 29   | 0.135  |
| ≥500                      | 28  | 17  | 11   |        |
| Serum CA125 (U/ml)        |     |     |      |        |
| <500                      | 29  | 8   | 21   | 0.003**|
| ≥500                      | 50  | 31  | 19   |        |

\(X^2\) Test was used to calculate the association between categorical variables. **p < 0.01.

---

Suggesting that mRNA stability change is the main cause of TRPC3 upregulation in the PLAA downregulated group.

Considering that m\(^A\)A modification is a common regulation model of mRNA at the post-transcriptional level, including mRNA stability [15]. First, we regulated m\(^A\)A modification by modulating the expression of METTL3, the main methyltransferase of m\(^A\)A modification. We knocked down METTL3, and interestingly found remarkably reduced TRPC3 mRNA stability (Fig. 5C), mRNA stability (Fig. 6D), mRNA level (Fig. 6E), and protein level (Fig. 6F) in A2780 and HO8910 cells. To further demonstrate the essential role of m\(^A\)A in the regulation of TRPC3, we replaced N\(^\text{6}\)-methylated adenosine (A) with thymine (T) in the m\(^A\)A consensus sequence of TRPC3 mRNA to establish a mutant TRPC3 that resists m\(^A\)A modification (Fig. 6F), and found that the luciferase activity was decreased in cells transfected with TRPC3-WT plasmid, but not mutant ones, when METTL3 was silenced (Fig. 6G).

Further, to investigate whether PLAA mediates TRPC3 by m\(^A\)A modification, we carried out a rescue assay, and found that the elevated m\(^A\)A modification level and the prolonged half-life of TRPC3 mRNA induced by PLAA depletion was reversed by METTL3 knockdown (Fig. 7H, I). Moreover, the elevation of TRPC3 mRNA and protein level induced by PLAA knockdown was also retrieved by attenuation of METTL3 (Figs. 6, K; S6C). Our results together indicate that PLAA regulates the expression of TRPC3 mRNA via m\(^A\)A modification.
Fig. 3  TRPC3 is negatively correlated with PLAA expression. A The heat map of differentially expressed mRNAs between A2780 cells with PLAA knockdown and without. RT-qPCR analysis of differentially expressed mRNAs in A2780 cells transfected with PLAA siRNAs (B) and A2780-M cells transfected with PLAA plasmids (C). The red frame shows TRPC3. D Immunoblot analysis of TRPC3 protein levels between A2780 cells with PLAA knockdown and without. E Immunoblot analysis of TRPC3 protein levels between A2780-M cells with PLAA overexpression and without. F Immunoblot analysis of PLAA and TRPC3 expression in A2780-M and A2780 cells. G RT-qPCR analysis of PLAA and TRPC3 expression in 56 ovarian tumor tissues. H Representative IHC staining images of PLAA and TRPC3 in ovarian cancer tissues (×200 and ×400 magnifications). Data are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Fig. 4 TRPC3 behaves as an oncogene and acts as a downstream target of PLAA. A RT-qPCR analysis of TRPC3 expression in 56 tissue samples of ovarian cancer and 12 tissue samples of ovarian benign tumor. B RT-qPCR analysis of TRPC3 expression in ovarian cancer tissues of late stages and early stages. C Kaplan–Meier analysis of progression-free survival of patients from TCGA data with different TRPC3 expression. A2780-M cells were transfected with two TRPC3 siRNAs or negative control. TRPC3 expression was determined by RT-qPCR (D) or immunoblot analysis (E). F A2780-M cells were transfected with two TRPC3 siRNAs or negative control. Cellular migration and invasion were detected by transwell assay. Scale bar, 100 μm. G Cellular migration and invasion of A2780-M cells treated with Pry3 or DMSO were detected by transwell assay. Scale bar, 100 μm. H, I A2780-M cells were transfected with PLAA plasmid, PLAA plasmid plus TRPC3 plasmid, and negative control, respectively (H). A2780 cells were transfected with PLAA siRNA, PLAA siRNA plus TRPC3 siRNA, PLAA siRNA plus Pry3 treatment (2 μM, 24 h), and negative control, respectively (I). Cellular migration and invasion were detected by transwell assay. Scale bar, 100 μm. J Ovarian cancer cells were orthotopically transplanted into SCID mice, and mice were intravenously treated with DMSO or Pry3 (5 mg/kg) for twice a week from the first week after implantation. Representative bioluminescence images of dissected primary and metastatic ovarian cancer at the time of execution. The photon count indicated the tumor burden. Data are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns no significant.
and in vivo experiments further showed that the PLAA upregulation inhibited migration and invasion of ovarian cancer cells, conversely, PLAA downregulation promoted migration and invasion of ovarian cancer cells. PLAA overexpression also suppressed metastasis in the mouse model of orthotopic xenograft. Importantly, we found that patients with lower PLAA expression were associated with high-risk clinicopathological features, such as FIGO stage, lymph node metastasis and CA125 level, and presented shorter survival. All our findings suggest that PLAA acts as a tumor suppressor in ovarian cancer metastasis, and

---

**Figure A**

- **A2780-M**
  - 0 mM Ca
  - 1.8 mM Ca

**Figure B**

- **A2780-M**
  - DMSO
  - Pyr3

**Figure C**

- **A2780**
  - Ctrl
  - TRPC3-DE
  - Ctrl+BAPTA-AM
  - TRPC3-DE+BAPTA-AM

**Figure D**

- **A2780**
  - Migration
  - Invasion

**Figure E**

- Metastatic tumor
  - DMSO
  - Pyr3
  - BAPTA-AM

**Figure F**

- **A2780**
  - si-NC
  - si-PLAA
  - si-PLAA+BAPTA-AM
  - si-PLAA+si-TPRC3

**Figure G**

- **A2780**
  - Migration
  - Invasion

---

**References**

- Z. Shen et al. (2022) Oncogene (41:4145–4158)
PLAA may have a potential to be clinically used as a biomarker associated with patient prognosis and a therapeutic target in metastatic ovarian cancer.

The mechanism by which PLAA functions is unknown so far. We utilized RNA-seq to identify candidates of PLAA downstream targets, and found TRPC3 to be upregulated in ovarian cancer cells with PLAA knockdown and there was a reverse correlation between PLAA and TRPC3 expression in ovarian cancer cells and tissues. Previous studies showed that TRPC3 was a member of the transient receptor potential (TRP) channel superfamily [16, 17] and crucial for the level of calcium concentration [18]. Calcium ion, as one of the most important second messengers in intracellular signaling network, regulates lots of physiopathological processes, such as metastasis in cancer cells [19]. Increasing evidence has demonstrated that TRPC3 is involved in the regulation of physiological activities [18, 19] and plays an important role in tumor proliferation, invasion and migration, including lung cancer [21], gastric cancer [22], bladder cancer [23] and ovarian cancer [24]. Here, we also found that TRPC3 knockdown inhibited migration and invasion in ovarian cancer cells, whereas TRPC3 overexpression presented the opposite effect. We further validated that TRPC3 functioned through regulating intracellular 

It has been known that m6A modification plays an important role in RNA stability and production [15]. N6-methyladenosine (m\(^\text{A}\)) as the most common modification of eukaryotic mRNA [26], has attracted much attention. The methylation of m\(^\text{A}\) is regulated by “writers” (methyltransferases) and “erasers” (demethylases) [27]. The classical “writers” are comprised of methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14) [28] and Wilms tumor 1 associated protein (WTAP) [29], while the classical “erasers” include fat mass and obesity-associated (FTO) [30] and AlkB homolog 5 (ALKBH5) [31]. Recent studies have revealed the association of dysregulation of m\(^\text{A}\) modification with various cancers, including bladder [32], liver [33], ovarian [34], and other cancers. In this study, we found that PLAA downregulation still elevated TRPC3 mRNA level in the presence of transcription inhibitor, suggesting that the regulation of TRPC3 by PLAA does not occur at the transcriptional level. Therefore, we carried out the mRNA stability assay and found that PLAA knockdown remarkably elevated the TRPC3 mRNA stability. Thus, screening of candidates associated with m\(^\text{A}\) modification in PLAA regulating TRPC3 was performed, and METTL3 was only upregulated protein among 3 “writers” and 2 “erasers” when PLAA knocked down. METTL3 and METTL14 form a stable heterodimer to affect the metastatic potential of cancer cells via distinct mechanism [35, 36], for example, METTL3 promoted the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression [37]. We also identified that METTL3 downregulation neutralized the increased TRPC3 mRNA level, mRNA stability, mRNA level, and protein level induced by PLAA knockdown, suggesting that m\(^\text{A}\) modification contributes to PLAA regulating TRPC3 mRNA level. The m\(^\text{A}\) modification can result in different biologic process through different reader proteins. Previous study has revealed that IGF2BP3s contribute to mRNA stability [38] and IGF2BP1 and IGF2BP3 are associated with poor disease outcome in ovarian cancer [39, 40]. Thus, protein IGF2BP2s are possible to be potential readers in TRPC3 m\(^\text{A}\) modification.

Another function of PLAA is regulation of protein ubiquitination that is a common and dynamic post-translational modification in nearly all eukaryotic biology [41]. Previous studies have demonstrated that PLAA targets ubiquitinated proteins and degrades through the ubiquitin-proteasome system [7, 42]. In this study, we found that PLAA affected the protein level of METTL3, but not mRNA level. Our ubiquitination assay showed that downregulation of PLAA was accompanied by reduced ubiquitination of METTL3. However, the detailed mechanism requires further investigation.

In summary, our study showed the association of downregulated PLAA with ovarian cancer metastasis and poorer prognosis of patients, PLAA inhibits migration and invasion of ovarian cancer cells via regulating TRPC3 and intracellular calcium level, and suppressed metastasis of orthotopic xenograft in mouse model. PLAA downregulates METTL3 via proteasome degradation pathway, and the METTL3-mediated m\(^\text{A}\) modification contributes to PLAA modulating TRPC3 mRNA (Fig. 8). Our findings demonstrate a suppressive role, as well as underlying mechanism, of PLAA in ovarian cancer metastasis, which may provide a potential approach to block ovarian cancer metastasis in clinic.

**MATERIALS AND METHODS**

**Patient specimens**

This study was approved by the Ethics Committee of Women’s Hospital, School of Medicine, Zhejiang University (granted number: IRB-20210147-R). All tissue samples were gathered from our hospital and informed consent was obtained from each patient before surgery. No patients underwent radiotherapy or chemotherapy before surgery. The patient information was listed in Table S1. All pathological diagnosis was re-reviewed by an expert pathologist.
Animal studies
All animal experiments were approved by Animal Ethical and Welfare Committee of Zhejiang Chinese Medical University (granted number: IACUC-20191216-02). Female severe combined immunodeficiency (SCID) mice, aged 4–6 weeks, were used as the orthotopic xenografts model. Mice were anesthetized by peritoneal injection of 0.3% pentobarbital (0.25 ml/10 g), the luciferase-expressed cells (1 × 10^6 cells in 10 μl PBS) were injected into the left ovary that was pulled out from the small abdominal midline incision, and the bio-gel was applied for preventing cells leaking into the abdominal cavity. Tumor development and metastasis were measured by monitoring luciferase activity at different time points.
monitored once a week by using the In Vivo Imaging System (IVIS) Lumina LT system (PerkinElmer, USA) after peritoneal injection of 150 mg/kg D-luciferin. Seven days after transplantation, bioluminescence intensity was applied to randomize mice into groups with different treatments to make sure similar level of bioluminescence in each group. To accurately assess the metastatic tumors, the primary tumors were dissected and the photon values of metastatic tumors were obtained. Dissected tissues were quickly fixed in 4% paraformaldehyde and embedded in paraffin for Hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining.

Cell culture
The human epithelial ovarian cancer cell lines A2780 and A2780-M cell lines were kindly gifted by the Cancer Research Institute, Zhejiang Cancer hospital, China. HO8910 and HO8910PM were obtained as described previously [43]. The normal ovarian epithelial cell line, IOSE-80, was kindly gifted by Prof. Lu Yan, Zhejiang University. These cells were authenticated by DNA(STR) profiling. Cells were incubated at 37 °C in a 5% CO2 incubator with humidified environment, and cultured with RPMI-1640 medium (BasalMedia, China), which were routinely supplemented with 10% fetal bovine serum (Everyday Green, China), penicillin (100 units/ml) and streptomycin (100 μg/ml).

LC-MS/MS label-free quantitative proteomics
Ovarian cancer cells (three independent samples in each group) were cracked in 300 μl lysis buffer, sonicated and centrifuged at 12,000 × g for 10 min. The supernatant was then collected, and measured the concentration by Bicinchoninic Acid Assay. The 10 μg proteins of each sample were acquired and separated by 12% SDS-PAGE gel. Other protein extracts were incubated for digestion at 37 °C for 16 h with Lys-C/Trypsin. The digested peptides were desalted by C18-Reverse-Phase SPE Column, and then the column was washed to elute the peptides by 0.1% trifluoroacetic acid. MS analysis was performed by a Q-Exactive mass spectrometer (Thermo scientific, USA). Full MS scans were acquired in the mass range of 350–1500 m/z. The ten most intense peaks in MS were fragmented with c, y, b, and search against Human Protein Database.

RNA sequencing
A2780 cells were transfected according to manufacturer’s protocol. The total RNA was extracted by TRIzol Reagent (Invitrogen, USA). RNA purity and quantification were evaluated using the NanoDrop 2000 spectrophotometer (Thermo Scientific, USA). RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, USA). The samples with RNA Integrity Number (RIN) ≥ 7 were used for library construction by using TruSeq Stranded mRNA LT Sample Prep Kit (Illumina, USA) according to the manufacturer’s instructions. And these libraries were sequenced on an Illumina HiSeq X Ten sequencing platform by OE Biotech. Co., Ltd (China). Differential gene expression analysis was done using the R package DEseq2. P value < 0.05 and log2|fold change| > 1 was set as the threshold for significantly differential expression. Hierarchical cluster analysis of DEGs was performed to demonstrate the expression pattern of genes in different groups and samples.

Western blot analysis and immunohistochemistry
For western blot analysis, cells were lysed by RIPA, and protein samples were separated by 10% SurePAGE gels (GenScript, USA) and transferred to 0.22 μm PVDF membranes (Bio-Rad, USA) using the eBlot L1 protein transfer system (GenScript, USA). At room temperature, 5% milk was used to block the membrane. Membrane was exposed to ImageQuant LAS 4000 mini (Cytiva, Japan).

For immunohistochemistry analysis, the formalin-fixed and paraffin-embedded samples were first deparaffinized and rehydrated, followed by PBS washing. Antigen retrieval was performed in 0.01 M sodium citrate buffer (pH 6.0) at 100 °C for 15 min. The positive cells were scored as: 1 for 0%–25%, 2 for 26%–50%, 3 for 51%–75% and 4 for 76%–100%. Staining intensity was scored as: 1 for negative, 2 for weak, 3 for moderate, and 4 for strong staining. The score for each microscopic field was obtained by multiplying the two parts of score, the sum was acquired by adding the scores of the five microscopic fields. The antibodies used were listed in Table S4.

Transwell assay and wound healing assay
The 24-well transwells (8 μm pore size, Falcon, USA) were used for evaluating cell invasion and migration ability. A total of 1 × 10^4 cells were seeded in ibidi culture insert (ibidi, Germany). The incubation field was obtained by multiplying the two parts of score, the sum was acquired by adding the scores of the five microscopic fields. The antibodies used were listed in Table S4.

RNA decay assay
To evaluate the RNA stability, the culture medium was supplemented with 5 μg/ml actinomycin D (Sigma-Aldrich, USA), then cells were collected at indicated different time points. Total RNA was isolated and subjected to RT-qPCR subsequently to analyze the relative abundance of TRPC3 mRNA (relative to 0 h).
Fig. 7  PLAA promotes METTL3 degradation via the ubiquitin-mediated pathway in ovarian cancer. A Expression of m^6^A writers (METTL3, METTL14, and WTAP) and erasers (ALKBH5 and FTO) were determined by immunoblot analysis. B RNA immunoprecipitation assays in PLAA-knockdown cells using METTL3 antibody to enrich TRPC3. The enrichment was calculated as input %. C A2780 and HO8910 cells were transfected with PLAA siRNAs or negative control, and METTL3 expression was determined by RT-qPCR. D PLAA-knockdown cells were treated with 50 μg/ml of cycloheximide (CHX) for different hours. PLAA and METTL3 expressions were detected by immunoblot analysis. E A2780-M and HO8910PM cells with or without PLAA overexpression were treated with 40 μM MG132 or 20 μM chloroquine (CQ) for 8 h. PLAA and METTL3 expressions were detected by immunoblot analysis. F A2780 and HO8910 cells were transfected with ubiquitin (Ub) and PLAA siRNA. Cell lysates were immunoprecipitated with METTL3 antibody followed by immunoblot analysis with ubiquitin antibody. Data are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns no significant.
MeRIP-qPCR
m^A modifications of individual genes were determined using MeRIP-qPCR assay. RNA was isolated and randomly fragmented into 100 nucleotides or less, followed by the immunoprecipitation with 5 μg m^A antibody (ABclonal, China) or anti-Rabbit IgG which was linked to PierceTM Protein A/G Magnetic Beads (Thermo Fisher Scientific, USA). The bound RNAs were washed and eluted with elution buffer, purified through phenol-chloroform extraction. Further enrichment was calculated by qPCR and the corresponding m^A enrichment in each sample was calculated by normalizing to the input.

RNA immunoprecipitation (RIP)
RIP analysis was performed using Magna RIP Kit (Millipore, Germany) according to manufacturer’s illustrations. Briefly, magnetic beads were mixed with 5 μg anti-METTL3 (Abclonal, China) or anti-Rabbit IgG before the addition of cell lysates (approximately 2 × 10^7 cells for each sample). After washing with RIP wash buffer for three times, the beads were incubated with cell lysates at 4 °C overnight. The beads were washed three times with wash buffer containing RNase inhibitor and Co-precipitated RNAs were eluted from immunoprecipitated complex and purified for further analysis using RT-qPCR. Relative enrichment was calculated as input%.

Dual-luciferase reporter assay
Wild-type (WT) or mutant (Mut) TRPC3 were cloned into plasmid synthesized by Genechem (China) which was comprised of firefly luciferase and renilla luciferase. For mutant plasmid, Adenosine (A) in m^A motif was replaced by Thymine (T). The dual-luciferase assays were performed after transfection for 48 h by using Dual-Luciferase Reporter Assay kit (Yeasen, China) according to manufacturer’s protocol.

Measurement of intracellular calcium ion concentration
Measurement of intracellular calcium release was performed as previously described [44]. Cells were seeded in a 4-well imaging chamber. After confluence to 70%, the cells were loaded with 5 μM Fluo-4 AM (Beyotime, China) Ca^{2+} indicator and incubated at 37 °C for 30 min. Thereafter, cells washed and incubated with HEPES buffer containing 1.8 mM Ca^{2+}. The confocal microscope FV1000 (Olympus, Japan) was used to detect the fluorescence intensity every 10 s. Fluo-4 was excited at 488 nm, and data were expressed normalized to baseline fluorescence (F/F0).

CCK-8 assay
Ovarian cancer cells were transfected with plasmid or siRNA for 24 h. Then an appropriate quantity of cells was seeded in 96-well plates. CCK-8 solution (Dojindo, Japan) was added into each well and incubated for 2 h at 0, 24, 48, 72, and 96 h after adhering to the plates. Optical density 450 nm value in each well was determined by a spectrophotometer reader (Thermo Fisher Scientific, USA).

Statistical analysis
Statistical analyses were conducted with the SPSS 22.0 and GraphPad Prism 8.0 software. All experiments were performed in triplicate. Measured data were represented as the mean ± SD. One-way analysis of variance (ANOVA) or two-tail Student’s t test was applied to compare quantitative data, while the nonparametric χ^2 test was used to analyze qualitative data. P values for each analysis are marked on figures, and the level of statistical significance was defined as P < 0.05 (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).

DATA AVAILABILITY
All data created and analyzed during this current work are involved in this published article (and its supplementary information files).

REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–96.
3. Cortés-Guiral D, Hübner M, Alyami M, Bhart A, Ceelen W, Glehen O, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Prim. 2021;7:91.
4. Sommerfeld L, Finkernagel F, Jansen JM, Wagner U, Nist A, Stiewe T, et al. The multicellular signalling network of ovarian cancer metastases. Clin Transl Med. 2021;11:e633.
5. Rubin J, Guoping C, Zhiguo Z, Maowei N, Danying W, Jianguo F, et al. Establishment and characterization of a highly metastatic ovarian cancer cell line. BioMed Res Int. 2018:2018:3972534.
6. Beatty BG, Qi S, Pienkowski M, Herbrick JA, Scheidt T, Zhang Z.M, et al. Chromosomal localization of phospholipase A2 activating protein, an Ets2 target gene, to 9p21. Genomics. 1999;62:529–32.
7. Mullally JE, Chernova T, Wilkinson KD. Doa1 is a Cdc48 adapter that possesses a novel ubiquitin binding domain. Mol Cell Biol. 2006;26:822–30.
8. Papadopoulos C, Kirchner P, Bug M, Grum D, Koerver L, Schulze N, et al. VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy. EMBO J. 2017:36:135–50.
9. Falik Zaccai TC, Savitzki D, Zivony-Elboum Y, Vilboux T, Fitzs EC, Shoval Y, et al. Phospholipase A2-activating protein is associated with a novel form of leukoencephalopathy. Brain. 2017;140:370–86.
10. Sasaki S, Kitagawa Y, Sekido Y, Minna JD, Kuwano H, Yokota J, et al. Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene. 2003;22:3792–8.
11. Goddard DH, Bomalaski JS, Clark MA. Phospholipase A2 activating protein induces tumor regression. Drug N Perspect. 1998;11:104–10.

12. Moccia F, Lucariello A, Guerra G. TRPC3-mediated Ca signals as a promising strategy to boost therapeutic angiogenesis in failing hearts: The role of autologous endothelial colony forming cells. J Cell Physiol. 2018;233:3901–17.

13. Monteth GJ, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. Nat Rev Cancer. 2017;17:367–80.

14. Cullen PJ, Lockyer PJ. Integration of calcium and Ras signalling. Nat Rev Mol Cell Biol. 2002;3:339–48.

15. Peer E, Rechavi G, Dominissini D. Epitranscriptomics: regulation of mRNA metabolism through modifications. Curr Opin Chem Biol. 2017;41:93–8.

16. Wang H, Cheng X, Tian J, Xiao Y, Tian T, Xu F, et al. TRPC channels: structure, function, regulation and recent advances in small molecule probes. Pharmacol Ther. 2020;209:107497.

17. Koivisto A-P, Belvisi MG, Gaudet R, Szlazaki A. Advances in TRP channel drug discovery: from target validation to clinical studies. Nat Rev Drug Discov. 2021;21:41–59.

18. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. Annu Rev Physiol. 2006;68:619–47.

19. Clapham DE. Calcium signaling. Cell. 2007;131:1047–58.

20. Numaga-Tomita T, Oda S, Shimashita T, Nishimura A, Mangnoul S, Nishida M. TRPC3 channels in cardiac fibrosis. Front Cardiovasc Med. 2017;4:56.

21. Jiang HN, Zeng B, Zhang Y, Daskoulidou N, Fan H, Qu J-M, et al. Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human non-small cell lung cancer. PLoS ONE. 2013;8:e87637.

22. Lin D-C, Zheng S-Y, Zhang Z-G, Luo J-H, Zhu Z-L, Li L, et al. TRPC3 promotes tumorigenesis of gastric cancer via the CNB2/1GSK3β1B/ATF2 signaling pathway. Cancer Lett. 2021;519:211–25.

23. Kim JM, Heo K, Choi J, Kim K, An W. The histone variant MacroH2A regulates Ca2+ influx through TRPC3 and TRPC6 channels. Oncogenesis. 2013;2:e77.

24. Yang SL, Cao Q, Zhou KC, Feng YJ, Wang YZ. Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene. 2009;28:1320–8.

25. Goes AM, Bertero T, Boezé A, Friard J, Bourget J, Pisano S, et al. Matrix stiffening and EGF-R cooperate to promote the collective invasion of cancer cells. Cancer Res. 2018;78:5229–42.

26. Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by mi6A modification. Trends Genet. 2020;36:177–88.

27. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20:608–19.

28. Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, et al. Structural basis of N6-adenosine methylation by the METTL3–METTL14 complex. Nature. 2016;534:575–8.

29. Ping X-L, Sun B-F, Wang L, Xiao W, Yang X, Wang W-J, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177–89.

30. Li F, Qi J, Zeng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885–7.

31. Zeng G, Dahl JA, Niu Y, Fedorcsak P, Huang C-M, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18–29.

32. Han J, Wang J-Z, Yang X, Yu H, Zhou R, Lu H-C, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in mi6A-dependent manner. Mol Cancer. 2019;18:110.

33. Chen M, Wei L, Law C-T, Tsang FH-C, Shen J, Cheng CL-H, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;68:254–70.

34. Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EF3C translation. Nucleic Acids Res. 2020;48:38316–31.

35. Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, et al. m6A RNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p–YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2021;14:32.

36. Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z, et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019;18:142.

37. Bi X, Li X, Liu D, Guo H, Yao G, Wang L, et al. METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-miRNA-1246. Cell Death Discov. 2021;7:237.

38. Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin J, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.

39. Muller S, Bley N, Glazi M, Busch B, Rousseau V, Misiai D, et al. IGF2BP1 enhances an aggressive tumor cell phenotype by impairing mRNA-directed down-regulation of oncogenic factors. Nucleic Acids Res. 2018;46:6285–303.

40. Hsu KF, Shen MR, Huang YF, Cheng YM, Lin SH, Chow NH, et al. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer. 2015;113:414–24.

41. Roberts JZ, Crawford N, Longley DB. The role of ubiquitination in apoptosis and necroptosis. Cell Death Differ. 2022;29:272–84.

42. Pashkova N, Gakh L, Winistorfer SC, Yu L, Ramaswamy S, Piper RC. WD40 repeat propellers define a ubiquitin-binding domain that regulates turnover of F box proteins. Mol Cell. 2010;40:433–43.

43. Shen X, Wang C, Zhu H, Wang Y, Yang X, Cheng X, et al. Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells. J Ovarian Res. 2021;14:38.

44. Balajnyam E, De Lorenzo MS, Xie L-H, Iwatsubo M, Shen C, Goydos JS, et al. Exchange protein directly activated by cyclic AMP increases melanoma cell migration by a Ca2+/dependent mechanism. Cancer Res. 2010;70:5607–17.

ACKNOWLEDGEMENTS
We thank our laboratory members and teachers for critical discussions. Thanks for the technical support by the core facilities, Zhejiang University School of Medicine. This work was supported by National Natural Science Foundation of China (Grant number: 82072856) and the Key Research and Development Program of Zhejiang Province, China (Grant number: 2019C03010).

AUTHOR CONTRIBUTIONS
Conceptualization, ZS and LG; Methodology, ZS, LG, YL, JZ and JW; Investigation, ZS, LG, YL, LW, ST, and JW; Data curation, ZS, LG, YL, JZ and JW; Resources, WL, XC, XWa, ZB; Writing—Original Draft, ZS; Writing—Review & Editing, WL, XX, LG, and LW; Funding acquisition, WL and XC; Supervision, WL and SZ. The authors read and approved the final manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
All the collection of specimens was approved by the ethical committee of the Women’s Hospital, Zhejiang University School of Medicine and informed consent was obtained. Animal experiments were approved by Animal Ethical and Welfare Committee of Zhejiang Chinese Medical University.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41388-022-02411-w.

Correspondence and requests for materials should be addressed to Weiguo Lu.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022